Depomed Hot Flash Drug May Finally Be On Its Way To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite the product’s rocky history, Depomed says it is ready to file its non-hormonal hot flash treatment Serada (extended-release gabapentin) based on a recent meeting with FDA. But a mixed Phase III dataset raises doubts about approvability.